Physician profile
Timothy Ko
NPI 1285847699
$7,028.00
in general payments reported to CMS, 2019-2025
32 companies · $353 in 2025
The $353 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,097 · 2020: $475 · 2021: $490 · 2022: $804 · 2023: $1,663 · 2024: $146 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,723.86 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Daiichi Sankyo INC. | $390.38 | 2019 | |
| Saluda Medical Americas, INC. | $320.11 | 2023 | Evoke Scs |
| Scilex Pharmaceuticals INC. | $267.38 | 2019-2023 | Ztlido |
| Nevro Corp. | $210.62 | 2019-2021 | |
| Tersera Therapeutics LLC | $148.01 | 2019 | |
| Abbott Laboratories | $122.71 | 2020-2025 | Proclaim |
| Teva Pharmaceuticals USA, INC. | $105.64 | 2019-2020 | |
| Sentynl Therapeutics, INC. | $87.48 | 2019 | |
| Curonix LLC | $72.13 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Vertos Medical, INC. | $67.69 | 2019-2020 | |
| Redhill Biopharma INC. | $53.98 | 2020-2022 | |
| Pfizer INC. | $50.92 | 2019 | |
| Stryker Corporation | $48.91 | 2025 | Mild Device Kit |
| Vertical Pharmaceuticals, LLC | $45.83 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Assertio Therapeutics, INC. | $41.91 | 2019-2020 | |
| Allergan, INC. | $34.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.29 | 2019 | |
| Pacira Therapeutics, INC. | $23.80 | 2019 | |
| Flowonix Medical Incorporated | $19.19 | 2020 | |
| Spr Therapeutics, INC | $18.17 | 2024 | Sprint Pns System |
| Masimo Corporation | $16.34 | 2023 | Na |
| Si-Bone, INC. | $15.80 | 2019 | |
| Biodelivery Sciences International, INC. | $15.63 | 2020 | |
| Globus Medical, INC. | $14.70 | 2025 | Senza |
| Ultragenyx Pharmaceutical INC. | $14.15 | 2022 | |
| Bioventus LLC | $13.69 | 2019 | |
| Amgen INC. | $13.28 | 2019 | |
| Tanabe Pharma America, INC. | $13.11 | 2019 | |
| Medtronic Vascular, INC. | $11.05 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10.90 | 2019 | |
| Collegium Pharmaceutical, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.